BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37494669)

  • 21. Systematic adaptation of the adherence improving self-management strategy to support breast cancer survivors' adherence to adjuvant endocrine therapy: An intervention mapping approach.
    Janssen AM; Dam J; Prins J; Buffart LM; de Bruin M
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13721. PubMed ID: 36263723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a community pharmacy-based intervention to enhance adherence to adjuvant endocrine therapy among breast cancer survivors guided by the Intervention Mapping approach.
    Labonté M; Guillaumie L; Dionne A; Dorval M; Nabi H; Lemieux J; Provencher L; Lauzier S
    Res Social Adm Pharm; 2020 Dec; 16(12):1724-1736. PubMed ID: 32205070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence trajectories of adjuvant endocrine therapy in the five years after its initiation among women with non-metastatic breast cancer: a cohort study using administrative databases.
    Lambert-Côté L; Bouhnik AD; Bendiane MK; Bérenger C; Mondor M; Huiart L; Lauzier S
    Breast Cancer Res Treat; 2020 Apr; 180(3):777-790. PubMed ID: 32086655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breast cancer patients' experiences of adherence and persistence to oral endocrine therapy: A qualitative evidence synthesis.
    Clancy C; Lynch J; OConnor P; Dowling M
    Eur J Oncol Nurs; 2020 Feb; 44():101706. PubMed ID: 32007696
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
    Lambert LK; Balneaves LG; Howard AF; Gotay CC
    Breast Cancer Res Treat; 2018 Feb; 167(3):615-633. PubMed ID: 29110151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Patient's Voice: Adherence, Symptoms, and Distress Related to Adjuvant Endocrine Therapy After Breast Cancer.
    Jacobs JM; Walsh EA; Park ER; Berger J; Peppercorn J; Partridge A; Horick N; Safren SA; Temel JS; Greer JA
    Int J Behav Med; 2020 Dec; 27(6):687-697. PubMed ID: 32495240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Women with breast cancer's perceptions of nurse-led telephone-based motivational interviewing consultations to enhance adherence to adjuvant endocrine therapy: a qualitative study.
    Gagné M; Lauzier S; Lemay M; Loiselle CG; Provencher L; Simard C; Guillaumie L
    Support Care Cancer; 2022 Jun; 30(6):4759-4768. PubMed ID: 35133477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to adjuvant endocrine therapy for breast cancer: a qualitative exploration of attribution of symptoms among post-menopausal women.
    Lee AY; Lyons AT; Makris V; Kamaraju S; Stolley MR; Neuner JM; Flynn KE
    Support Care Cancer; 2024 Apr; 32(4):265. PubMed ID: 38565669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Codevelopment of a Text Messaging Intervention to Support Adherence to Adjuvant Endocrine Therapy in Women With Breast Cancer: Mixed Methods Approach.
    Green SMC; French DP; Hall LH; Bartlett YK; Rousseau N; Raine E; Parbutt C; Gardner B; ; Smith SG
    J Med Internet Res; 2023 May; 25():e38073. PubMed ID: 37223964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Women's Beliefs on Early Adherence to Adjuvant Endocrine Therapy for Breast Cancer: A Theory-Based Qualitative Study to Guide the Development of Community Pharmacist Interventions.
    Humphries B; Collins S; Guillaumie L; Lemieux J; Dionne A; Provencher L; Moisan J; Lauzier S
    Pharmacy (Basel); 2018 Jun; 6(2):. PubMed ID: 29890738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient experiences and views on pharmaceutical care during adjuvant endocrine therapy for breast cancer: A qualitative study.
    En-Nasery-de Heer S; Tromp VNMF; Westerman MJ; Konings I; Beckeringh JJ; Boons CLM; Timmers L; Hugtenburg JG
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13749. PubMed ID: 36300863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors associated with intentional and unintentional non-adherence to adjuvant endocrine therapy following breast cancer.
    Brett J; Fenlon D; Boulton M; Hulbert-Williams NJ; Walter FM; Donnelly P; Lavery B; Morgan A; Morris C; Watson E
    Eur J Cancer Care (Engl); 2018 Jan; 27(1):. PubMed ID: 27901302
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interventions to promote adherence to endocrine therapy among breast cancer survivors: A meta-analysis.
    Finitsis DJ; Vose BA; Mahalak JG; Salner AL
    Psychooncology; 2019 Feb; 28(2):255-263. PubMed ID: 30511789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation.
    Gomaa S; Lopez A; Slamon R; Smith R; Lapitan E; Nightingale G; Miller SM; Wen KY
    Support Care Cancer; 2023 Nov; 31(12):719. PubMed ID: 38008817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
    Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
    Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Managing Symptom Distress: Key Factors for Patients on Adjuvant Endocrine Therapy for Breast Cancer.
    Post KE; Ahmad Z; Jankauskaite G; Centracchio J; Oswald L; Horick N; Park ER; Temel JS; Greer JA; Jacobs J
    J Pain Symptom Manage; 2024 Jan; 67(1):88-97. PubMed ID: 37816436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the role of physician communication about adjuvant endocrine therapy among breast cancer patients on active treatment: a qualitative analysis.
    Farias AJ; Ornelas IJ; Hohl SD; Zeliadt SB; Hansen RN; Li CI; Thompson B
    Support Care Cancer; 2017 Jan; 25(1):75-83. PubMed ID: 27557832
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The lived experience of breast cancer patients on adjuvant endocrine therapy: Side effects and coping strategies during the first year of medication initiation.
    Gomaa S; Lopez A; Slamon R; Smith R; Telushi E; Lapitan E; Nightingale G; Miller S; Wen KY
    Res Sq; 2023 Jan; ():. PubMed ID: 36778385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Healthcare Provider Perspectives on Adherence to Adjuvant Endocrine Therapy after Breast Cancer.
    Lambert LK; Balneaves LG; Howard AF; Chia SLK; Gotay CC
    Curr Oncol; 2021 Apr; 28(2):1472-1482. PubMed ID: 33918560
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors Associated with Adherence to Adjuvant Endocrine Therapy Among Privately Insured and Newly Diagnosed Breast Cancer Patients: A Quantile Regression Analysis.
    Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
    J Manag Care Spec Pharm; 2016 Aug; 22(8):969-78. PubMed ID: 27459660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.